Resource Logo
AIDS Weekly Plus

New Findings from McGill University AIDS Center in the Area of HAART Published




 



2012 OCT 1 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Current study results on HAART have been published. According to news reporting originating in Montreal, Canada, by NewsRx journalists, research stated, "Highly active antiretroviral therapy (HAART) consists of a combination of drugs to achieve maximal virological response and reduce the potential for the emergence of antiviral resistance. Despite being the first antivirals described to be effective against HIV, reverse transcriptase inhibitors remain the cornerstone of HAART."

The news reporters obtained a quote from the research from McGill University AIDS Center, "There are two broad classes of reverse transcriptase inhibitor, the nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs). Since the first such compounds were developed, viral resistance to them has inevitably been described; this necessitates the continuous development of novel compounds within each class. In this review, we consider the NRTIs and NNRTIs currently in both preclinical and clinical development or approved for second-line therapy and describe the patterns of resistance associated with their use as well as the underlying mechanisms that have been described. Due to reasons of both affordability and availability, some reverse transcriptase inhibitors with a low genetic barrier are more commonly used in resource-limited settings."

According to the news reporters, the researchers concluded: "Their use results in the emergence of specific patterns of antiviral resistance and so may require specific actions to preserve therapeutic options for patients in such settings."

For more information on this research see: Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors. Antimicrobial Agents and Chemotherapy, 2012;56(10):5000-8. (American Society for Microbiology - www.asm.org; Antimicrobial Agents and Chemotherapy - aac.asm.org)

Our news correspondents report that additional information may be obtained by contacting E.L. Asahchop, McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada (see also HAART).

Keywords for this news article include: Antiinfectives, Antiretroviral Agents, Drugs, HAART, Quebec, Canada, Therapy, Montreal, Genetics, HIV/AIDS, Proteins, Proteomics, RNA Viruses, Retroviridae, HIV Infections, Vertebrate Viruses, Primate Lentiviruses, Enzymes and Coenzymes, North and Central America, Reverse Transcriptase Inhibitors.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC



 


Copyright © 2012 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.



Information in this article was accurate in October 1, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.